GeneDx at Jefferies London: Strategic Expansion in Pediatrics

GeneDx (WGS) told investors at Jefferies London that whole-exome/genome volumes jumped 33% to 26,000 tests last quarter as it pursues a strategy to expand beyond geneticists into 60,000 general pediatricians (a newly validated ~$2.5bn TAM following AAP guideline updates) and scale NICU testing (currently <5% penetration, with research suggesting ~$150k savings per baby). Management reported an average cash reimbursement of about $3,800 per test (targeting an 80% payment rate), expects gross margins of 70–71% (up ~600 bps) and plans to maintain adjusted EBITDA profitability by 2026 while investing in payer engagement, EPIC Aura integrations, simplified “one-minute” ordering and AI/automation to cut analysis costs. Key near-term execution risks include payer reactions and transient denial-rate volatility as volumes shift to new ordering physician types, but sustained margin tailwinds and state Medicaid coverage expansion (now 36 states) underpin revenue and profitability upside.

Analysis

GeneDx reported whole-exome and whole-genome volumes increased 33% year-over-year to 26,000 tests in the last quarter while executing a strategic push beyond expert geneticists into 60,000 general pediatricians (AAP guideline update creates a cited ~$2.5bn TAM) and into NICUs where current testing penetration is <5% and published Seattle Children’s data suggests potential ~$150,000 annual savings per baby. Management has launched an early-access program with several dozen pediatricians, is building a one-minute ordering workflow for 2026, and has 12 health systems integrated with EPIC Aura to streamline ordering.

Management reported an average cash reimbursement of about $3,800 per test and a current cash collection rate near 55% with a theoretical target of 80% and a when-paid average near $7,000; Medicaid whole-genome coverage now spans 36 states and Medicaid represents ~40% of volume with uneven state coverage driving payment variability. Gross margins are guided to 70–71% (up ~600 bps) driven by COGS reductions across a stack described as roughly one-third reagents, one-third wet-lab labor and one-third post-sequence analysis, where AI and automation are targeted to drive further savings.

Management is committed to adjusted EBITDA profitability by 2026 while investing in commercial expansion and payer engagement, but notes an 18–24 month timetable to materially ramp general pediatrics and cautions on transient denial-rate volatility as new physician types scale. Key execution sensitivities and catalysts to monitor are realized payment-rate improvements, further state Medicaid adoptions, EPIC Aura / NICU volume lift, and documented cost reductions from automation against stated margin and profitability targets.

Key Decisions for Investors

• Consider selectively adding to positions on pullbacks if the company sustains or improves the ~55% cash collection rate toward the 80% target and gross margins converge to the 70–71% guidance,
• Monitor the 18–24 month ramp metrics (general pediatrician order growth, early-access conversion rates, EPIC Aura activations and NICU test volumes) as primary revenue catalysts and re-rate points,
• Limit position size or hedge exposure ahead of large-volume rollouts from general pediatricians given management's warning of potential transient denial-rate volatility as payers adjust,
• Track quarterly KPIs including tests volumes, average reimbursement per test, paid-rate percentage, Medicaid state additions (36 states to date) and adjusted EBITDA trajectory toward 2026 and tighten risk controls on misses